continue to site
"Trust in the Lord with all thine heart; and lean not unto thine own understanding. In all thy ways acknowledge him, and he shall direct thy paths."
- Proverbs 3:5-6
August 2022
Issue
health living travel food shop events jobs
home health living travel food shop events jobs trending magazine Contact Us Advertise
Dr. Nikhil Thaker of Arizona Oncology Inducted into American Brachytherapy Society of Fellows
By Christina Caldwell - Thursday Jul 21, 2022
Arizona Oncology is proud to announce Nikhil G. Thaker, MD, MHA, MBA, CMQ, DABR, DABPM, FABS, has been inducted into the 2022 class of the American Brachytherapy Society Fellows (FABS) by the American Brachytherapy Society (ABS) Board of Directors.

Brachytherapy, a cancer treatment in which radioactive material is sealed inside a seed or pellet and implanted inside the body, requires a high degree of skill and expertise. The ABS Fellowship is granted to physicians with significant contributions and accomplishments in the field of brachytherapy, and nominees are evaluated by their contributions to research, patient care, education, or leadership. The Fellowship is prestigious as only six physicians have been inducted nationwide in the past two years.

Dr. Thaker is double-board certified in radiation oncology and clinical informatics and works with leading experts in all aspects of radiation oncology. He treats a wide range of cancers including prostate, breast, and gynecologic cancers, and has helped develop leading-edge cancer therapies, including novel therapeutic combinations for brain tumors. He has worked with national leaders in healthcare innovation at Harvard Business School and holds national leadership positions in the American Society for Radiation Oncology (ASTRO) and The US Oncology Network.

“We are extremely proud of Dr. Thaker and of all the hard work he puts forth as a physician and on behalf of the Arizona community. An ABS Fellowship is a significant professional recognition and a tribute to Dr. Thaker’s contributions and accomplishments in the field of brachytherapy,” said Joseph Buscema, MD. “It is an honor to have an ABS fellow at Arizona Oncology and a significant benefit to patients in our community.”

Dr. Thaker is based out of Tucson-Craycroft Radiation Oncology, which is located at 2625 N. Craycroft Rd., #100, Tucson, AZ 85712. To schedule a consultation with Dr. Thaker, call 520-324-4214.

About Arizona Oncology

Arizona Oncology is one of the largest medical groups in Arizona, with more than 50 physicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. Since its inception in 1998, Arizona Oncology has led with the philosophy that it’s beneficial to provide cancer therapies in a community setting, close to patients' homes and support systems. Arizona Oncology specializes in Medical, Gynecologic, and Radiation Oncology, Hematology, Breast Surgery, Colorectal Surgery, Urology, Research, Genetic Risk Assessment, and patient ancillary programs. The physicians and their staff treat patients in many communities throughout the state including Glendale, Goodyear, Green Valley, Phoenix, Prescott, Prescott Valley, Scottsdale, and Tucson. For more information, visit http://www.arizonaoncology.com.

Arizona Oncology is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 1,200 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Arizona Oncology also participates in clinical trials through US Oncology Research, which has played a role in more than 85 FDA-approved cancer therapies, approximately one-third of all cancer therapies approved by the FDA to
 date.